Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 4/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | THPO | P40225 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | GMNN | O75496 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3587894 | 0.85 | TACR1 (0.44) | TACR1CYP2D6TP53CYP1A2CYP3A4 | |
| SCHEMBL2712838 | 0.85 | TACR1 (0.44) | TACR1CYP2D6TP53CYP1A2CYP3A4 | |
| SCHEMBL2712836 | 0.85 | TACR1 (0.44) | TACR1CYP2D6TP53CYP1A2CYP3A4 | |
| SCHEMBL1709471 | 0.77 | KDM4E (0.40) | LMNAKDM4EALDH1A1POLBGAA | |
| SCHEMBL8195514 | 0.77 | PSEN1 (0.40) | KDM4EALDH1A1POLBGAAMAPK1 | |
| SCHEMBL1709470 | 0.76 | KDM4E (0.40) | KDM4EALDH1A1POLBGAAMAPK1 | |
| SCHEMBL31506543 | 0.75 | TACR1 (0.51) | TACR1CYP2D6TP53CYP1A2CYP3A4 | |
| SCHEMBL13604483 | 0.74 | ALDH1A1 (0.47) | TACR1CYP2D6TP53CYP1A2CYP3A4 | |
| SCHEMBL1039190 | 0.74 | KDM4E (0.42) | KDM4EALDH1A1POLBGAAMAPK1 | |
| SCHEMBL8209905 | 0.74 | KDM4E (0.42) | KDM4EALDH1A1POLBGAAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2013171-B1 | PIPERIDINES AND RELATED COMPOUNDS FOR TREATMENT OF ALZHEIMER S DISEASE | MERCK SHARP & DOHME (GB) | 2013-05-15 | — | — | EP | disclosed |
| US-8420622-B2 | Silylated piperidine derivatives | Merck, Sharp & Dohme, Corp. (US) | 2013-04-16 | — | — | US | disclosed |
| US-8420622-B2 | Silylated piperidine derivatives | Merck, Sharp & Dohme, Corp. (US) | 2013-04-16 | — | — | US | disclosed |
| US-8389547-B2 | Piperidines and related compounds for the treatment of Alzheimer's disease | MERCK SHARP & DOHME LLC | 2013-03-05 | — | — | US | disclosed |
| EP-2007724-B1 | PIPERIDINE DERIVATIVES FOR TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME (GB) | 2012-05-02 | — | — | EP | disclosed |
| US-7985758-B2 | Piperidine derivatives for treatment of Alzheimer's disease | MERCK, SHARP & DOHME LIMITED (GB) | 2011-07-26 | — | — | US | disclosed |
| US-20100093665-A1 | SILYLATED PIPERIDINE DERIVATIVES | MERCK SHARP & DOHME CORP. | 2010-04-15 | — | — | US | disclosed |
| US-20100048623-A1 | PIPERIDINES AND RELATED COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME LLC | 2010-02-25 | — | — | US | disclosed |
| EP-1805141-B1 | PIPERIDINES AND RELATED COMPOUNDS FOR TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME (GB) | 2010-01-20 | — | — | EP | disclosed |
| US-7638629-B2 | Piperidines and related compounds for treatment of alzheimer's disease | Merck Sharp & Dohme Ltd, (GB) | 2009-12-29 | — | — | US | disclosed |
| US-20090186919-A1 | PIPERIDINE DERIVATIVES FOR TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME LIMITED (GB) | 2009-07-23 | — | — | US | disclosed |
| US-20080021043-A1 | Piperidines and Related Compounds for Treatment of Alzheimer's Disease | MERCK SHARP & DOHME LTD. (GB) | 2008-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021043-A1 | Piperidines and Related Compounds for Treatment of Alzheimer's Disease | PSEN1, PSEN2, APP | TACR1 380/4885CYP2D6 3883/4885TP53 4339/4885 |
| US-20100093665-A1 | SILYLATED PIPERIDINE DERIVATIVES | PSEN1, PSEN2, SRM | TACR1 32/4885CYP2D6 4123/4885TP53 2143/4885 |
| US-20090186919-A1 | PIPERIDINE DERIVATIVES FOR TREATMENT OF ALZHEIMER'S DISEASE | BACE1, PSEN1, PSEN2 | TACR1 1010/4885CYP2D6 3633/4885TP53 3327/4885 |
| US-20100048623-A1 | PIPERIDINES AND RELATED COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | BACE1, PSEN1, BACE2 | TACR1 316/4885CYP2D6 2952/4885TP53 4078/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.